Risk factors of tuberculosis after liver transplant in a tertiary care hospital

被引:0
作者
Leong, Lih-Ying [1 ]
Lin, Po-Chang [1 ]
Chi, Chih-Yu [1 ]
Chou, Chia-Huei [1 ]
Lu, Min-Chi [1 ]
Liao, Wei-Chih [2 ]
Ho, Mao-Wang [1 ]
Wang, Jen-Hsien [1 ]
Jeng, Long-Bin [3 ]
机构
[1] China Med Univ Hosp, Dept Internal Med, Div Infect Dis, 2 Yu Der Rd, Taichung 40447, Taiwan
[2] China Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taichung, Taiwan
[3] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
关键词
Mycobacterium tuberculosis; Liver transplantation; Risk factors; COMPUTED-TOMOGRAPHY; REDUCED TACROLIMUS; RECIPIENTS; INFECTION; EVEROLIMUS; DISEASES; SOCIETY; MTOR;
D O I
10.1016/j.jmii.2019.08.006BY-
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Tuberculosis (TB) is a serious opportunistic infection in liver transplant (LT) recipients with a high rate of morbidity and mortality. This study aims to clarify the frequency and risk factors for tuberculosis in LT recipients. Methods: A total of 884 LT recipients were investigated retrospectively at China Medical University Hospital, Taichung, Taiwan. We performed a case-control study (1:2) to investigate the potential risk factors and disease onset of TB after LT. Results: Among the 884 LT recipients, 25 of TB cases (2.8%) were reported from 2009 to 2016. The overall incidence of TB was 744 cases per 100,000 patient-year, which was 18-fold higher than the general population in Taiwan. The median time to develop TB after liver transplant was 20 months. Of the TB cases, 15 were pulmonary TB and 10 were extra-pulmonary TB. Five cases of those extra-pulmonary TB occurred in the first post-transplant year. Overall five-year survival rate was 63.3%. Multivariate analyses identified apical fibrotic change in pre transplant computed tomographic (CT) finding and the exposure to mammalian target of rapamycin (mTOR) inhibitors before TB event as independent risk factors for TB development (Odd ratio (OR) 10.79, 95% confidence interval (CI), 1.73-67.49, p = 0.01; OR 3.847, 95% CI 0.80-18.51, P = 0.09, respectively). Conclusion: TB incidence in LT recipients is high in this study. Among those post-transplant recipients with long-term immunosuppression, abnormal CT finding and exposure to mTOR inhibitors before liver transplant might be the risk factors for TB. Copyright & ordf; 2019, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:312 / 318
页数:7
相关论文
共 32 条
[1]   Sirolimus: More cause for alarm? [J].
Agarwal, Parul D. ;
Lucey, Michael R. .
LIVER TRANSPLANTATION, 2012, 18 (09) :1003-1004
[2]   Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain [J].
Aguado, JM ;
Herrero, JA ;
Gavalda, J ;
TorreCisneros, J ;
Blanes, M ;
Rufi, G ;
Moreno, A ;
Gurgui, M ;
Hayek, M ;
Lumbreras, C ;
Morales, JM ;
Pahissa, A ;
Margerit, C ;
Prada, JL ;
Kindelan, JM ;
Ros, F ;
Pallardo, LM ;
Carratala, J ;
Gudiol, F ;
Gonzalez, J ;
Vilardell, J ;
Guirado, L ;
Rabella, N .
TRANSPLANTATION, 1997, 63 (09) :1278-1286
[3]   Tuberculosis in Solid-Organ Transplant Recipients: Consensus Statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology [J].
Aguado, Jose Maria ;
Torre-Cisneros, Julian ;
Fortun, Jesus ;
Benito, Natividad ;
Meije, Yolanda ;
Doblas, Antonio ;
Munoz, Patricia .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (09) :1276-1284
[4]  
[Anonymous], 2018, WHO-Global Tuberculosis Report 2018
[5]   De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000-2003 Phase II Prospective Randomized Trial [J].
Asrani, S. K. ;
Wiesner, R. H. ;
Trotter, J. F. ;
Klintmalm, G. ;
Katz, E. ;
Maller, E. ;
Roberts, J. ;
Kneteman, N. ;
Teperman, L. ;
Fung, J. J. ;
Millis, J. M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (02) :356-366
[6]   QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases [J].
Bartalesi, F. ;
Vicidomini, S. ;
Goletti, D. ;
Fiorelli, C. ;
Fiori, G. ;
Melchiorre, D. ;
Tortoli, E. ;
Mantella, A. ;
Benucci, M. ;
Girardi, E. ;
Cerinic, M. M. ;
Bartoloni, A. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (03) :586-593
[7]   Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area [J].
Benito, N ;
Sued, O ;
Moreno, A ;
Horcajada, JP ;
González, J ;
Navasa, M ;
Rimola, A .
TRANSPLANTATION, 2002, 74 (10) :1381-1386
[8]   Tuberculosis in lung transplant recipients [J].
Bravo, C ;
Roldán, J ;
Roman, A ;
DeGracia, J ;
Majo, J ;
Guerra, J ;
Monforte, V ;
Vidal, R ;
Morell, F .
TRANSPLANTATION, 2005, 79 (01) :59-64
[9]   The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement [J].
Bumbacea, Dragos ;
Arend, Sandra M. ;
Eyuboglu, Fusun ;
Fishman, Jay A. ;
Goletti, Delia ;
Ison, Michael G. ;
Jones, Christine E. ;
Kampmann, Beate ;
Kotton, Camille N. ;
Lange, Christoph ;
Ljungman, Per ;
Milburn, Heather ;
Morris, Michele I. ;
Muller, Elmi ;
Munoz, Patricia ;
Nellore, Anoma ;
Rieder, Hans L. ;
Sester, Urban ;
Theodoropoulos, Nicole ;
Wagner, Dirk ;
Sester, Martina .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) :990-1013
[10]   Incidence and Risk Factors for Tuberculosis After Liver Transplantation in an Endemic Area: A Nationwide Population-Based Matched Cohort Study [J].
Chen, C. -Y. ;
Liu, C. -J. ;
Feng, J. -Y. ;
Loong, C. -C. ;
Liu, C. ;
Hsia, C. -Y. ;
Hu, L. -Y. ;
Lin, N. -C. ;
Hu, Y. -W. ;
Yeh, C. -M. ;
Chen, T. -J. ;
Yang, C. -C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (08) :2180-2187